Skip to main content

Table 7 Bayesian method estimates of indirect probabilities of passing different visual acuity thresholds at month 6 for patients with BRVO

From: Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion

Improvement or worsening at Month 6

Probability for Group§ (95% CrI)

Relative risk* (95% CrI)

 

Ranibizumab

Dexamethasone

 

Gain ≥20 letters

0.419 (0.338,0.503)

0.187 (0.086,0.316)

0.45 (0.23,0.86)

Gain ≥10 letters and <20 letters

0.353 (0.275,0.435)

0.221 (0.115,0.337)

0.63 (0.36,1.10)

Loss <10 letters and gain <10 letters

0.199 (0.136,0.269)

0.332 (0.184,0.466)

1.67 (0.97,2.89)

Loss ≥10 letters and <20 letters

0.015 (0.002,0.041)

0.051 (0.015,0.118)

3.43 (0.59,19.97)

Loss ≥20 letters

0.015 (0.002,0.041)

0.210 (0.041,0.529)

14.21 (2.21,91.25)

  1. §Mean of 100000 samples from posterior distributions of probability for change in BCVA from baseline category.
  2. *Ratio of mean probabilities with credible interval based on Delta method on log scale.
Back to article page

BMC Medical Research Methodology

ISSN: 1471-2288

Contact us